GeneTx Biotherapeutics LLC

Biopharma companies work hard to stack their pipelines with promising candidates. But which candidates are the most promising? A recent report from Evaluate finds that the top three pipeline assets

It remains early days but Ultragenyx Pharmaceutical Inc. likes its chances to succeed in the rare neuro-genetic disorder Angelman syndrome where Ovid Therapeutics, Inc. notably flamed out in 2020.

Ovid Therapeutics, Inc. is hitting the pause button on its program to develop OV101 (gaboxadol) for Angelman syndrome following the failure of the Phase III NEPTUNE trial. The company plans a full an

Former Novartis AG CEO Joe Jimenez and former Novartis Institutes for BioMedical Research Inc. (NIBR) founding president Mark Fishman have brought their drug development expertise to the start-up